Clinical trial · Interventional
Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer
NCT00626873CI-TRIAL-00027052completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer. PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Definity | Drug | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Definity
- description
- Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
- interventionNames
- Drug: Definity
- Other: medical chart review
Primary outcomes (1)
- measure
- Ovarian microvascularity
- timeFrame
- 2 years
- description
- To evaluate the use of contrast agents to depict the tumor microvascularity to detect ovarian cancer.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of adnexal mass * Scheduled to undergo surgical oophorectomy PATIENT CHARACTERISTICS: * Not pregnant or nursing * Negative pregnancy test * No known respiratory failure as manifested by signs and symptoms of carbon dioxide retention or hypoxemia * No pulmonary vasculitis * No known history of severe emphysema * No known history of pulmonary emboli * No other condition that causes pulmonary hypertension due to compromised pulmonary arterial vasculature * No known history of severe pulmonary hypertension (i.e., systolic pulmonary artery pressures \> 90 mm Hg) * No known history of congenital heart defect that creates a bidirectional or right-to-left shunt * No worsening or clinically unstable congestive heart failure * No known acute myocardial infarction or acute coronary syndromes * No known serious ventricular arrhythmias * Not at high risk for arrhythmia due to prolongation of the QT interval * No known or suspected hypersensitivity to blood, blood products, or albumin * No known hypersensitivity to perflutren * No known or suspected hypersensitivity to octafluoropropane or any other ingredients of perflutren lipid microspheres (Definity®) * No mental status problems, illiteracy, or other circumstance that would preclude giving informed consent PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (1)
- RESULTFleischer AC, Lyshchik A, Hirari M, Moore RD, Abramson RG, Fishman DA. Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements. J Oncol. 2012;2012:302858. doi: 10.1155/2012/302858. Epub 2012 Apr 26. PMID 22619674